{"name":"NephroNet, Inc.","slug":"nephronet-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Acthar Gel 80 UNT/ML Injectable Solution","genericName":"Acthar Gel 80 UNT/ML Injectable Solution","slug":"acthar-gel-80-unt-ml-injectable-solution","indication":"Infantile spasms (West syndrome)","status":"marketed"},{"name":"Oral Tab Tacrolimus","genericName":"Oral Tab Tacrolimus","slug":"oral-tab-tacrolimus","indication":"Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas)","status":"marketed"}]}],"pipeline":[{"name":"Acthar Gel 80 UNT/ML Injectable Solution","genericName":"Acthar Gel 80 UNT/ML Injectable Solution","slug":"acthar-gel-80-unt-ml-injectable-solution","phase":"marketed","mechanism":"Acthar Gel is a synthetic adrenocorticotropic hormone (ACTH) that stimulates the adrenal cortex to produce and release cortisol and other corticosteroids.","indications":["Infantile spasms (West syndrome)","Nephrotic syndrome","Systemic lupus erythematosus","Rheumatoid arthritis","Acute exacerbations of multiple sclerosis"],"catalyst":""},{"name":"Oral Tab Tacrolimus","genericName":"Oral Tab Tacrolimus","slug":"oral-tab-tacrolimus","phase":"marketed","mechanism":"Tacrolimus is a calcineurin inhibitor that suppresses T-cell activation by blocking the phosphatase calcineurin, thereby preventing the transcription of pro-inflammatory cytokines.","indications":["Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas)","Atopic dermatitis","Autoimmune conditions (off-label use in various settings)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}